A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-124 in Healthy Adult Participants
Latest Information Update: 04 Feb 2026
At a glance
- Drugs ARGX 124 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors argenx
Most Recent Events
- 04 Feb 2026 New trial record